Top-Rated StocksTop-RatedPositive News SentimentPositive NewsNASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $13.28 -0.99 (-6.94%) Closing price 04:00 PM EasternExtended Trading$13.28 0.00 (0.00%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sutro Biopharma Stock (NASDAQ:STRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$12.83▼$14.2150-Day Range$14.27▼$25.6752-Week Range$7.15▼$43.85Volume298,745 shsAverage Volume264,827 shsMarket Capitalization$220.20 millionP/E RatioN/ADividend YieldN/APrice Target$49.50Consensus RatingBuy Company Overview Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary cell-free protein synthesis and protein-engineering platforms to design and manufacture complex biologic medicines, including antibody-drug conjugates (ADCs) and immuno-oncology treatments. Sutro’s principal product candidate is luveltamab tazevibulin, also known as luvelta or STRO-002, an ADC designed to target folate receptor alpha, a protein expressed in several cancers. The company has also developed additional investigational programs directed at cancer-related targets and continues to evaluate new therapies generated through its research platforms. Founded in 2003 and headquartered in South San Francisco, California, Sutro conducts research and clinical development activities that support potential treatments for patients in the United States and other international markets. William J. Newell has served as the company’s chief executive officer and has been associated with Sutro since its early development.AI Generated. May Contain Errors. Read More Sutro Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 75% of companies evaluated by MarketBeat, and ranked 199th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSutro Biopharma has a consensus price target of $49.50, representing about 272.7% upside from its current price of $13.28.Amount of Analyst CoverageSutro Biopharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($8.41) to ($6.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Sutro Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.35% of the float of Sutro Biopharma has been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 6.47.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 11.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment1.89 News SentimentSutro Biopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sutro Biopharma this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders1.80% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Stock News HeadlinesSutro Biopharma Announces Participation at the 17th Annual World ADC Conference3 hours ago | markets.businessinsider.comVaxcyte Prices $1 Billion in Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesOctober 6, 2026 | quiverquant.comQHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 12 at 1:00 AM | Banyan Hill Publishing (Ad)Vaxcyte Announces Webcast and Conference Call to Present Topline Data from OPUS-1 Phase 3 Trial of VAX-31 in AdultsOctober 4, 2026 | quiverquant.comQSutro Biopharma, Inc. (NASDAQ:STRO) Stock Has Average Price Target of $49.50 According to BrokeragesOctober 4, 2026 | americanbankingnews.comWells Fargo & Company Initiates Coverage on Sutro Biopharma (NASDAQ:STRO)October 2, 2026 | americanbankingnews.comSutro Biopharma, Inc. Announces Appointment of Lucas Donigian as Senior Vice President, Business Development, Effective September 28, 2026September 30, 2026 | marketscreener.comMSutro Biopharma nomina Lucas Donigian come responsabile dello sviluppoSeptember 29, 2026 | it.investing.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $11.57 at the start of the year. Since then, STRO shares have increased by 14.8% and is now trading at $13.28. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($2.33) earnings per share for the quarter, missing the consensus estimate of ($2.19) by $0.14. The company had revenue of $9.84 million for the quarter, compared to analysts' expectations of $11.96 million. When did Sutro Biopharma's stock split? Sutro Biopharma's stock reverse split on Wednesday, December 3rd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $85 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,667,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings8/12/2026Today10/12/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 STRO's financial health is in the Yellow zone, according to TradeSmith. STRO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STRO CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees128Year Founded2003Price Target and Rating Average Price Target for Sutro Biopharma$49.50 High Price Target$60.00 Low Price Target$34.00 Potential Upside/Downside+273.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($11.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$191.09 million Net Margins-395.25% Pretax Margin-395.46% Return on EquityN/A Return on Assets-88.12% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$45.70 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value($15.43) per share Price / Book-0.86Miscellaneous Outstanding Shares16,581,000Free Float16,283,000Market Cap$219.86 million OptionableOptionable Beta1.49 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:STRO) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
